Table 2.
Treatment patterns among patients initiated with EPO 40,000 U or DARB 500 mcg
| EPO | DARB | P-value | |
|---|---|---|---|
| Mean administered dose per injection, (SD) | 41,979 U (5,772) | 488 mcg (100) | NA |
| Days between injections, mean (SD) | 12.0 (8.7) | 26.6 (14.9) | NA |
| Overall dose frequency, n (%) | NA | ||
| QW | 209 (49.8) | 0 (0.0) | |
| Q2W | 161 (38.3) | 8 (6.7) | |
| Q3W | 50 (11.9) | 112 (93.3) | |
| Mean cumulative ESA dose, (SD) | 295,058 U (192,387) | 1,750 mcg (870) | NA |
| Mean ESA treatment duration, days (SD) | 60.9 (35.1) | 61.8 (32.3) | 0.888 |
| Mean (SD) number of Hb determinations during treatment duration | 7.7 (4.9) | 5.9 (4.1) | <0.001 |
| Mean (SD) number of office visits during treatment duration | 6.7 (6.4) | 8.1 (6.6) | 0.005 |
EPO epoetin alfa, DARB darbepoetin alfa, ESA erythropoiesis-stimulating agent, SD standard deviation, QW once per week, Q2W once every two weeks, Q3W once every three weeks